Netflix Declines to Raise Bid for Warner Bros. Discovery Amid Competing Paramount Skydance Offer 
Germany and China Reaffirm Open Trade and Strategic Partnership in Landmark Beijing Visit 
Strait of Hormuz LNG Crisis Triggers Global Energy Market Shock 
Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
U.S. Stocks Close Lower as Hot PPI Data, Nvidia Slide Weigh on Wall Street 
Gold Prices Rally in February as Geopolitical Risks and Economic Uncertainty Boost Safe-Haven Demand 
Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets 
Oil Prices Steady as US-Iran Nuclear Talks and Rising Crude Inventories Shape Market Outlook 
OpenAI Hires Former Meta and Apple AI Leader Ruomin Pang Amid Intensifying AI Talent War 
Dominican Republic Unveils Massive Rare Earth Deposits to Boost High-Tech and Energy Sectors 
MOEX Russia Index Hits 3-Month High as Energy Stocks Lead Gains 
Stock Market Movers: Dell, Block, Duolingo, Zscaler, CoreWeave, Autodesk, Rocket, MARA 
Ecuador Raises Tariffs on Colombian Imports to 50% Amid Border Security Dispute 
Anthropic Refuses Pentagon Request to Remove AI Safeguards Amid Defense Contract Dispute 
Middle East Airspace Shutdown Disrupts Global Flights After U.S.-Israel Strikes on Iran 
IMF Urges U.S. to Cut Fiscal Deficit to Reduce Trade and Current Account Gaps 
Meta Signs Multi-Billion Dollar AI Chip Deal With Google to Power Next-Gen AI Models 
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
